OBJECTIVES: This study aimed to investigate the early and late outcomes of patients undergoing aortic valve replacement (AVR) with previous coronary artery bypass grafting (CABG) and patent grafts.
INTRODUCTION
Improved survival following coronary artery bypass grafts (CABGs) means that a significant proportion of patients must undergo further surgery to treat degenerative aortic valve disease. Aortic valve replacement (AVR) is the current standard of care, but is more complex in the context of prior CABG. Additional operative risk is conferred by the presence of adhesions, the potential for injury to patent grafts and the need for relocation of sites for aortic perfusion and cross-clamping, cardioplegia delivery and aortotomy [1] . Damage to the patent left internal mammary artery (LIMA) pedicle is particularly detrimental and can occur if the graft is in close proximity to the posterior aspect of the sternum or during dissection and control of the LIMA graft for myocardial protection. Injury to the LIMA results in significant perioperative morbidity and mortality and denies the patient the proven long-term efficacy of the LIMA to LAD graft [2, 3] .
A major constraint on AVR post-CABG is the potential for cardioplegia washout through a patent LIMA during cardiopulmonary bypass (CPB). Several myocardial protective strategies have been proposed, including whole-heart dissection and intrathoracic clamping of the LIMA pedicle, supraclavicular or endovascular control of the LIMA, deep hypothermia with an unclamped LIMA and total circulatory arrest [4] . Each has its disadvantages: clamping or endovascular occlusion of the LIMA can result in graft injury and subsequent myocardial infarction, while leaving the LIMA unclamped can lead to poor cardioplegia delivery to the LAD-dependent myocardium. Also, the mechanism of cardioplegia provision should be established a priori. Antegrade cardioplegia can be ineffective when there are proximal stenoses of the left coronary artery, while retrograde cardioplegia is unreliable for protection of the right ventricle. Careful pre-operative assessment with the aid of angiographic and cross-sectional imaging is warranted to determine the optimal surgical approach for individual patients.
Assessments of the effectiveness of open AVR following CABG are particularly important in the light of recent advances in percutaneous aortic valve interventions. Transcatheter aortic valve intervention (TAVI) has proven superiority over medical management in high-risk patients with aortic stenosis [5] . TAVI may negate some of the operative risks associated with prior CABG, but there is concern surrounding the durability of prostheses and the need for reintervention. Studies are required that report contemporary outcomes of open AVR post-CABG to determine whether it is ethical to make comparisons with TAVI in randomized trials. Here, we report a single-centre' experience of AVR following previous CABG in a large cohort of patients.
METHODS

Patients
A retrospective analysis of a prospectively collected database of patients undergoing first-time AVR following previous CABG was performed. Exclusion criteria included an absence of all patent coronary artery bypass grafts and previous AVR or TAVI. Prior concomitant procedures other than those on the aortic valve were permitted. Between January 2000 and March 2010, a total of 104 patients were identified ( Table 1 ). The median age of participants was 75 years (range 37-90; inter-quartile range: 69-79 years) and 83.6% were males. Major comorbidities included previous myocardial infarction (n = 60, 57.6%), hypertension (n = 66, 63.5%), hyperlipidaemia (n = 81, 77.8%), diabetes mellitus (n = 18, 17.3%), chronic obstructive pulmonary disease (n = 18, 17.3%), cerebrovascular disease (n = 12, 11.5%) and chronic renal disease (>200 µmol/l or long-term dialysis; n = 8: 7.7%) ( Table 1) . Pre-operative New York Heart Association (NYHA) classification was ≥3 in 63 patients (60.5%). The mean pre-operative logistic EuroSCORE was 25.37 ± 16.8 and the median time from prior sternotomy was 9 years (range 1-25 years). A LIMA to LAD graft had been used in 75 patients (72.1%) and remained patent in 72 of these (96.0%).
Pre-operative investigations
Pre-operative work-up was aimed at delineating coronary graft anatomy and establishing safety to undergo open AVR. This comprised a chest radiograph, electrocardiogram, echocardiography and invasive coronary angiography. Careful consideration was given to the course of the patent grafts in relation to the posterior aspect of the sternum and the sternal wires. Carotid ultrasonography was performed selectively in patients who had suffered a cerebrovascular event (including transient ischaemic attack) in the 6 months preceding surgery.
Surgical procedure
Surgery was performed through a midline sternotomy. In selected cases, CPB was established via the femoral vessels to allow for greater control during cardiac dissection. In most cases, CPB was established through aorto-bicaval or aorto-atrial cannulation. Four distinct methods were used to provide myocardial protection and control of the LIMA. In the majority of cases, the LIMA was dissected free from adhesions and controlled with the use of either a mini-clamp (n = 35, 46.6%) or vascular snugger (n = 19, 25.3%). In a further six patients (8.0%), the LIMA was controlled with an endovascular balloon, while two patients (2.6%) underwent total circulatory arrest. The LIMA was left uncontrolled with moderate to deep hypothermia (28-32°C) in a further 12 cases (16.0%). Cold blood cardiolpgeia was administered via either the retrograde or antegrade route. In a selection of patients, antegrade and retrograde cardioplegia were combined to maximize myocardial protection. AVR was performed using standardized methods, including aortic cross-clamping, aortotomy, excision of the disease valve leaflets and insertion of the new prosthesis. Bioprosthetic valves were implanted in 87 patients (83.6%) and mechanical valves were used in 17 (16.3%) ( Table 2 ). Isolated AVR was performed in 66 patients, while concomitant procedures were undertaken in 38 patients, including CABG (n = 33), aortic root replacement (n = 2), replacement of the ascending aorta (n = 2) and mitral valve repair (n = 2). The mean CPB and aortic cross-clamp (AXC) times were 128.0 ± 65.9 and 67.2 ± 30.4 min, respectively.
Statistical analyses
The primary outcome of the study was overall survival defined as death by any cause from the first post-operative day. Patients were censored if they were lost to follow-up or were alive at final assessment. Statistical analysis was performed using Statistical Package for the Social Science Programme, SPSS Version 16.0 (SPSS Inc., Chicago, IL, USA) and Microsoft Excel. Data were expressed as frequency with percentage, mean with standard deviation (SD) or as median with lower and upper quartiles and range, as appropriate. The product-limit method of the Kaplan-Meier survival analysis was used to evaluate timedependent events in survival. Univariate analysis was performed to assess whether there was a relationship between 30-day mortality and late mortality (>30 day mortality) and the risk factors. Continuous variables were compared using the two-tailed Student's t-test, whereas categorical variables were compared using the χ 2 test or Fisher's exact test, as appropriate. Odds ratio and 95% confidence interval (CI) were recorded. Any risk factor that indicated a relationship with mortality was then added to a logistic regression model. Backward (step-wise) elimination was then used to further select important risk factors after adjusting for others. Any risk factor that reached statistical significance (P < 0.25) would be in the final model for re-operation. A P-value of <0.05 was considered statistically significant.
RESULTS
A total of 116 perioperative complications occurred in 45 patients (Table 3 ). Injury to the LIMA occurred in six patients (5.7%) and was identified and repaired in all patients during the index procedure. The median post-operative hospital stay was 10 days (range 4-183 days; inter-quartile range: 7-15.25 days). Thirty-day mortality occurred in eight patients (7.7%). Notably, this is significantly less than that predicted by the pre-operative logistic EuroScore. Univariate analysis (Table 4) showed that prolonged AXC time and the use of intra-operative IABP affected 30-day mortality, but multivariate analysis (Table 5 ) revealed prolonged AXC time (P = 0.03) and the presence of a previous LIMA to LAD graft (P = 0.04) as statistically significant risk factors for in-hospital death. There were 10 late deaths (after 30 days) in the series. Overall survival at 1 and 5 years was 89.4 ± 3.2 and 81.5 ± 5.5%, respectively (Fig. 1) . The univariate analysis is shown in Table 6 . However, multivariate regression (Table 7) demonstrated that new-onset atrial fibrillation (P = 0.04), post-operative acute kidney injury (AKI: increase in serum creatinine ≥50% above baseline or the need for new dialysis; P = 0.01) and concomitant CABG+MVR (P = 0.005) were associated with worse overall long-term survival. 
DISCUSSION
With the ageing population, more patients who have only mild aortic valve disease at the time of CABG are surviving long enough to require revision sternotomy and AVR. These procedures are particularly challenging because of the risk of damage to the LIMA or long saphenous vein grafts on reopening the chest or during cardiac dissection. LIMA injury is associated with a mortality rate of up to 50 [6] [7] [8] [9] and a 40% chance of perioperative myocardial infarction [10] . Despite this, AVR has proven efficacy and negates the dismal prognosis associated with conservative management of aortic stenosis. This study reports the short-and long-term outcomes of patients undergoing AVR following prior CABG and identifies perioperative variables that, on multivariate analysis, are associated with 30-day mortality and overall survival. Thirty-day mortality in this series was 7.7%, despite the inclusion of many moderate-to high-risk patients with multiple comorbidities. Indeed, the 30-day mortality rate is markedly lower than that predicted by the pre-operative logistic EuroScore. However, this operative risk assessment tool has been shown to overestimate mortality in patients undergoing revision aortic valve procedures [11] . Our results, therefore, reflect much of the current literature, where early mortality ranges from 0 to 18% [12] . We have shown that prolonged AXC time and the presence of a previous LIMA to LAD graft are independent predictors of 30-day mortality. Other studies have used multivariate methods to identify further associations between early mortality and perioperative variables [11, [13] [14] [15] [16] . Few publications have reported long-term survival outcomes for patients treated with AVR post-CABG. In this series, the actuarial survival was 89.4 ± 0.3 and 81.5 ± 0.5% at 1 and 5 years, respectively. Hoth et al. [17] reported a 5-year overall survival of 71%, whereas Fighali et al. [16] described survival rates of 96, 75 and 49% at 1, 5 and 10 years, respectively. Overall survival in our series, therefore, compares favourably with the literature, despite the inclusion of numerous moderate-or high-risk individuals. Multivariate analysis demonstrated that new-onset atrial fibrillation, postoperative AKI and concomitant CABG + MVR were associated with reduced long-term overall survival. In the only other study that has used multivariate analysis, risk factors for late mortality included pre-operative diabetes mellitus, post-operative acute respiratory distress syndrome and ventricular arrhythmias [16] . The incidence of LIMA injury reported in the literature ranges from 5 to 9% [3, 10, 13, 15] , which is broadly in accordance with the incidence of 5.7% observed in this series. Despite several studies reporting high mortality rates associated with LIMA injury on univariate analysis, most modern series incorporating multivariate regression have failed to demonstrate a link between LIMA injury and 30-day mortality or overall survival [10, [13] [14] [15] [16] . In our series, only the presence of a LIMA graft and not LIMA injury itself was predictive of 30-day mortality. Possible reasons for the lack of association between LIMA injury and outcome include improved recognition and intra-operative management of LIMA damage and the small number of patients with LIMA injury reported in published articles. In addition, the LIMA graft provides excellent perfusion of the myocardium, which may provide some perioperative cardiac protection and prevent ischaemic complications. Further prospective studies with large sample sizes are warranted to investigate this complicated association.
In the last decade, there have been significant advances in percutaneous aortic valve interventions. The results 'Arm B' of the PARTNER trial demonstrated a significant survival advantage for TAVI in high-risk patients with aortic stenosis compared with medical management alone [5] . Consequently, TAVI may now become the treatment of choice in patients in whom open AVR confers too great an operative risk. The subsequently published randomized comparison of TAVI versus open AVR in high-risk patients (PARTNER A) showed similar survival at 1-year follow-up [18] . In the context of our study, TAVI is a feasible option in patients with aortic stenosis and prior CABG and potentially negates the risks associated with revision sternotomy and damage to patent grafts. However, studies comparing TAVI with other procedures in moderate or low-risk populations may be unethical. This is because open AVR has been performed with such excellent safety, efficacy and durability over the last 40 years that equipoise has been lost. Indeed, our series reported 30-day mortality rates following AVR of just 7.7, compared with 5.0% (30-day all-cause mortality) following TAVI in 'Arm B' of the PARTNER trial. However, TAVI remains a novel technological innovation for which greater evidence of durability of implants is required before its use can be justified in low-or moderate-risk populations. As implementation of TAVI becomes more widespread, it is likely that retrospective comparative studies in patients who have undergone previous CABG will begin to appear and it is important that these are rigorous and can thus inform future trial design and clinical decision-making.
This study is retrospective and should be interpreted in the light of this limitation. It is possible that recall bias could have influenced the results; however, the data reported were entered on to a prospectively maintained database. In addition to this, no comparisons were made between treatment groups, which negate the effects of selection bias. This study is the second largest case series of AVR following previous CABG and has been conducted in a high-risk cohort of patients over a 10-year period. As such, it provides invaluable evidence that AVR post-CABG is both safe and has long-term effectiveness. It also provides data that could be invaluable to informing whether it would be ethical to perform randomized controlled trials of TAVI versus AVR in this cohort of patients.
In summary, we have shown that AVR following previous CABG is a safe procedure in specialist centres. In addition, long-term survival is excellent despite the inclusion of high-risk patients. Although further prospective studies comparing TAVI and AVR might be warranted in patients with previous CABG, the wealth of evidence currently supports open surgical intervention. 
